Navidea deals NA Lymphoseek rights to Cardinal Health in $310m deal

Navidea Biopharmaceuticals (NYSE:NAVB) said today that it inked a definitive asset purchase agreement with Cardinal Health (NYSE:CAH) for Navidea’s Lymphoseek product.

Dublin, Ohio-based Navidea said that it will receive $80 million at closing for it’s lymphatic mapping and lymph node biopsy product, plus the opportunity for $230 million in milestone payments through 2026. More than $20 million of that amount is guaranteed over the next 3 years.

Get the full story at our sister site, Drug Delivery Business News.

The post Navidea deals NA Lymphoseek rights to Cardinal Health in $310m deal appeared first on MassDevice.

from MassDevice http://ift.tt/2ftB3NY